Synlogic, Inc. (NASDAQ:SYBX – Get Rating) saw a significant increase in short interest in May. As of May 15th, there was short interest totalling 695,800 shares, an increase of 141.0% from the April 30th total of 288,700 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 296,800 shares, the short-interest ratio is presently 2.3 days.
Hedge Funds Weigh In On Synlogic
Institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new position in shares of Synlogic in the first quarter valued at approximately $27,000. Envestnet Asset Management Inc. grew its position in Synlogic by 273.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 78,671 shares of the biotechnology company’s stock worth $60,000 after buying an additional 57,604 shares in the last quarter. Millennium Management LLC grew its position in Synlogic by 333.6% during the fourth quarter. Millennium Management LLC now owns 95,434 shares of the biotechnology company’s stock worth $73,000 after buying an additional 73,422 shares in the last quarter. Ensign Peak Advisors Inc acquired a new stake in Synlogic during the first quarter worth approximately $79,000. Finally, UBS Group AG acquired a new stake in Synlogic during the first quarter worth approximately $84,000. Institutional investors and hedge funds own 56.46% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Chardan Capital dropped their target price on Synlogic from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, March 29th. HC Wainwright reissued a “buy” rating on shares of Synlogic in a research report on Thursday, April 27th.
Synlogic Price Performance
Synlogic (NASDAQ:SYBX – Get Rating) last posted its earnings results on Wednesday, March 29th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. Synlogic had a negative return on equity of 71.60% and a negative net margin of 5,952.43%. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.40 million. On average, analysts predict that Synlogic will post -0.88 EPS for the current year.
Synlogic Company Profile
Synlogic, Inc engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K.
- Get a free copy of the StockNews.com research report on Synlogic (SYBX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.